

Special Issue

Pharmacotherapy of Glioblastoma – Recent Improvements and Novel Perspectives

Message from the Guest Editors

Glioblastoma (GBM) is one of the most aggressive forms of cancer. Several factors, such as the presence of the blood-brain barrier, the high molecular and cellular heterogeneity of GBM, the presence within these tumors of a population of cells with stem-like properties, and the difficulties in developing specific targeted therapies, have hindered the development of effective GBM therapies. Remarkably, plasma membrane properties have a high impact on drug-membrane interactions and drug permeability, and therefore should be considered for the design of novel therapeutic approaches against GBM.

Authors are invited to submit original and review articles covering all aspects of emerging pharmacotherapeutic strategies to fight GBM. These include, but are not limited to, pharmaceutical nanotechnology, nanocarriers, immunotherapy, epigenetic modifiers, innovative analytical approaches, and natural-product-based drugs.

investigational therapies
pharmacological epigenetic modifiers
targeted therapy
nanotechnology
natural products
immunotherapy
resistance to therapy
glioma stem-like cells
electroanalytical methods
liposomes

Guest Editors

Dr. Magdalena Kusaczuk

Prof. Dr. Monika Naumowicz

Dr. Guillermo Velasco

Deadline for manuscript submissions



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/73938

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).